The impact of lithium prophylaxis on the course of bipolar disorder: A review of the research evidence

Bipolar Disorders

Volumn 2, Issue 2, 2000, Pages 93-101

  Maj, Mario ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Largo Madonna delle Grazie ^*  (Italy)

Author keywords

Bipolar disorder; Discontinuation; Lithium; Naturalistic studies; Placebo controlled trials; Predictors of response; Prophylaxis

Indexed keywords

CARBAMAZEPINE; LITHIUM DERIVATIVE; TRANQUILIZER;

BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SUICIDE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SUICIDE;

EID: 0034208880     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2000.020202.x     Document Type: Review

References (85)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151: suppl.
2. Suppes T, Calabrese JR, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DAB. Algorithms for the treatment of bipolar, manic-depressive illness. Psychopharmacol Bull 1995; 31: 469-474.
3. Expert Consensus Panel. Treatment of bipolar disorder. J Clin Psychiatry 1996; 57: suppl. 12A.
4. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999; 60: 9-21.
5. Markar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 1989; 155: 496-500.
6. Moncrieff J. Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569-574.
7. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller M. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997; 27: 281-289.
8. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds. Lithium in Medicine and Biology. Carnforth: Marius Press, 1993; 71-84.
9. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; ii: 326-330.
10. Melia PI. Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry 1970; 116: 621-624.
11. Coppen A, Noguera R, Bailey J, Burns BH, Swani MS, Hare EH, Gardner R, Maggs R. Prophylactic lithium in affective disorders: controlled trial. Lancet 1971; ii: 275-279.
12. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972; 2: 308-311.
13. Hullin RP, McDonald R, Allsopp MNE. Prophylactic lithium in recurrent affective disorders. Lancet 1972; i: 1044-1046.
14. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973; 28: 337-341.
15. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-425.
16. Stallone F, Shelley E, Mendlewicz J, Fieve RR. The use of lithium in affective disorders. III. A double blind study of prophylaxis in bipolar illness. Am J Psychiatry 1973; 130: 1006-1010.
17. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V. A double blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120.
18. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976; 133: 925-930.
19. Goodwin GM. Lithium revisited. A reply. Br J Psychiatry 1995; 167: 573-574.
20. Sachs GS, Lafer B, Truman CJ, Noeth M, Thibault AB. Lithium monotherapy: miracle, myth and misunderstanding. Psychiatric Ann 1994; 24: 299-306.
21. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665-671.
22. Symonds RL, Williams P. Lithium and the changing incidence of mania. Psychol Med 1981; 11: 193-196.
23. Dickson WE, Kendell RE. Does maintenance lithium therapy prevent recurrences of mania under ordinary clinical conditions? Psychol Med 1986; 16: 521-530.
24. Goldberg JF, Harrow M, Sands JR. Lithium and the longitudinal course of bipolar illness. Psychiatric Ann 1996; 26: 651-658.
25. Grof P. Admission rates and lithium therapy. Br J Psychiatry 1987; 150: 264-265.
26. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency. Br J Psychiatry 1994; 164: 741-746.
27. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
28. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorder. Am J Psychiatry 1998; 155: 638-645.
29. Gitlin MJ, Swendson J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
30. Maj M. Long-term impact of lithium prophylaxis on the course of bipolar disorder. In: Christodoulou G, Lecic-Tosevski D, Kontaxakis VP, eds. Issues in Preventive Psychiatry. Basel: Karger, 1999; 79-82.
31. Berghöfer A, Kossman B, Müller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996; 93: 349-354.
32. Kleindienst N, Greil W, Rüger B, Möller H-J. The prophylactic efficacy of lithium - transitory or persistent? Eur Arch Psychiatry Clin Neurosci 1999; 249: 144-149.
33. Dotti A, Bernini P. Indagine catamnestica sulle ragioni dell'interruzione della terapia continuativa con carbonato di litio. Riv Psichiatria 1979; 4: 293-307.
34. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989; 98: 535-538.
35. Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN. The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol 1995; 49: 127-147.
36. Angst J. Course of affective disorders. In: van Praag HM, Lader MH, Rafaelsen OJ, Sachar EJ, eds. Handbook of Biological Psychiatry. New York: Dekker, 1981; 225-242.
37. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. Br J Psychiatry 1998; 172: 23-28.
38. Maj M, Pirozzi R, Magliano L. Late non-response to lithium prophylaxis in bipolar patients: prevalence and predictors. J Affect Disord 1996; 39: 39-42.
39. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium 1992; 3: 15-21.
40. Mendlewicz J, Fieve RR, Stallone F. Relationship between effectiveness of lithium therapy and family history. Am J Psychiatry 1973; 130: 1011-1013.
41. Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 1974; 31: 189-192.
42. Maj M, Arena F, Lovero N, Pirozzi R, Kemali D. Factors associated with response to lithium prophylaxis in DSM-III major depression and bipolar disorder. Pharmacopsychiatry 1985; 18: 309-313.
43. Mander AJ. Clinical prediction of outcome and lithium response in bipolar affective disorder. J Affect Disord 1986; 11: 35-41.
44. Koukopoulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatrie-Neuropsychopharmakologie 1980; 13: 156-167.
45. Haag M, Heidorn A, Haag H, Greil W. Response to stabilising lithium therapy and sequence of affective polarity. Pharmacopsychiatry 1986; 19: 278-279.
46. Grof E, Haag M, Grof P, Haag H. Lithium response and the sequence of episode polarities: preliminary report on a Hamilton sample. Prog Neuro-Psychopharmacol Biol Psychiatry 1987; 11: 199-203.
47. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17: 237-241.
48. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991; 148: 1237-1239.
49. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
50. O'Connell RA, Mayo JA, Flatow L, Cuthberson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
51. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br J Psychiatry 1976; 129: 40-44.
52. Bauer MS, Whybrow PC. Rapid cycling bipolar disorder: clinical features, treatment, and etiology. In: Amsterdam J, ed. Refractory Depression. New York: Raven Press, 1991; 191-208.
53. Himmelhoch JM, Neil JF, May SJ, Fuchs CZ, Licata SM. Age, dementia, diskinesias, and lithium response. Am J Psychiatry 1980; 137: 941-945.
54. Fleischhacker WW. Pharmacological treatment of schizophrenia: a review. In: Maj M, Sartorius N, eds. Schizophrenia. Chichester: Wiley, 1999; 75-107.
55. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risk and implications. Harvard Rev Psychiatry 1993; 1: 131-144.
56. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154: 551-553.
57. Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998; 31: 210-215.
58. Schou M, Thomsen K, Baastrup PC. Studies on the course of recurrent endogenous affective disorders. Int Pharmacother 1970; 5: 100-106.
59. Grof P, Cakuls P, Dostal T. Lithium drop-outs: a follow-up study of patients who discontinued prophylactic treatment. Int Pharmacopsychiatry 1970; 5: 162-169.
60. Rifkin A, Quitkin F, Howard A. A study of abrupt lithium withdrawal. Psychopharmacology 1975; 44: 157-158.
61. Sashidharan SP, McGuire RJ. Recurrence of affective disorders after withdrawal of long-term lithium treatment. Acta Psychiatr Scand 1983; 68: 126-133.
62. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727-1729.
63. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels. Am J Psychiatry 1994; 151: 1522.
64. Baldessarini RJ. Risks of discontinuing maintenance treatments. In: Paper presented at the 149th Annual Meeting of the American Psychiatric Association, New York. May, 1996.
65. Maj M, Pirozzi R, Magliano L. Non-response to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810-1811.
66. Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera AC. Special treatment issues: maintaining and discontinuing psychotropic medications. In: Rush AJ, ed. Mood Disorders. Systematic Medication Management. Basel: Karger, 1997; 235-254.
67. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997; 154: 548-550.
68. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998; 155: 895-898.
69. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 (suppl. 2): 77-84.
70. Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behaviour: a review for clinicians. J Affect Disord 1998; 50: 253-259.
71. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161.
72. Thies-Flechtner K, Seibert W, Walther A, Greil W, Müller-Oerlinghausen B. In: Müller-Oerlinghausen B, Berghöfer A, eds. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgard: Thieme, 1994; 61-64.
73. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacolology 1981; 73: 95-96.
74. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-494.
75. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987; 150: 180-182.
76. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs. lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204.
77. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-118.
78. Kishimoto A, Ogura C, Hazama H, Inoue K. Long-term prophylactic effects of carbamazepine in affective disorder. Br J Psychiatry 1983; 143: 327-331.
79. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27: 138-145.
80. Denicoff KD, Smith-Jackson EE, Disney ER, Omar Ali S, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
81. Bowden CL. Long-term prophylactic treatment priorities in bipolar disorder. Eur Neuropsychopharmacol 1997; 7 (suppl. 2): S123-S124.
82. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. The use of valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50 (suppl. 3): 23-29.
83. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12 (suppl. 1): 53S-56.
84. Solomon DA, Ryan CE, Keitner GI, Miller IW, Tracie Shea M, Kazim A, Keller MB. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58: 95-99.
85. Keck PE Jr, McElroy SL, Stakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorders. J Clin Psychiatry 1998; 59 (suppl. 6): 74-81.